Similar mutations targeting Wnt pathway components are also frequent in HCC (15–33% of HCC patients carry activating mutations in ctnnb1 (coding for β-catenin)15, while 17% have inactivating mutations in axin or apc4,16) and have led to the conclusion that these mutations also act as dominant event to trigger oncogenic Wnt/β-catenin signaling in HCC. The gene discussed is CTNNB1; the disease is hepatocellular carcinoma.